Business Standard

Ranbaxy to market Australian liver cancer drug

Image

BS Reporter Mumbai
Ranbaxy Laboratories has signed an exclusive in-licencing agreement with Sirtex Medical, Australia, to promote and market Sirtex's SIR-Spheres. The product, approved by the US Food and Drug Authority, is used for the treatment of patients with inoperable tumors from primary colorectal cancer that have spread to the liver.

Sanjeev Dani, senior vice president & regional director, Asia & CIS, Ranbaxy, said, "We are pleased to partner Sirtex for this unique, high technology product. We shall work towards creating a productive relationship by complementing each others' strengths. The agreement will enable Ranbaxy to further strengthen our position in the oncology segment."

SIR-Spheres has been used to treat liver cancer patients in Australia, USA, Europe, New Zealand and Asia in a variety of clinical trials and general practice.

 

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 24 2007 | 5:37 PM IST

Explore News